Ctesi (chenodiol) 250MG drug
Ended Purchase Order Awarded Last action
- Contract number
- 36C25025P1221
- Awardee
-
Mirum Pharmaceuticals, Inc. UEI U8E2HFXRE9X3
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $227,874
Award facts
- Contract value 100% obligated
- $227,874.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Foster City, CA 94404, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $1,139 | |
| Original award | $226,735 |
About this award
Mirum Pharmaceuticals, Inc. was awarded a $227,874 firm fixed-price purchase order by the Department of Veterans Affairs' Veterans Integrated Service Network 10 for the supply of CTESI (Chenodiol) 250mg pharmaceutical product. The contract, issued on June 10, 2025, carries an ultimate completion date of June 9, 2026, and does not utilize a set-aside designation, indicating open competition for the procurement. Performance will occur at Mirum's facility in Foster City, California. This award reflects the VA's reliance on specialized pharmaceutical suppliers to support the healthcare needs of veterans, particularly for treatments addressing complex medical conditions.
Mirum Pharmaceuticals operates as a for-profit rare disease pharmaceutical manufacturer based in San Mateo, California, with an established federal contract portfolio focused on drug delivery to VA medical centers. Beyond this purchase order, the company maintains multiple contract vehicles under the GSA Pharmaceuticals and Drugs Federal Supply Schedule, including a blanket purchase agreement valued at $1.125 million through May 2026 for Livmarli, used to treat Alagille syndrome. The company's federal contracting approach demonstrates consistent capability in providing specialized pharmaceutical therapies directly to federal healthcare agencies, with pricing structured as firm fixed-price arrangements across multiple Veterans Integrated Service Networks.
Quick answers
Who was awarded contract 36C25025P1221?
36C25025P1221 was awarded to Mirum Pharmaceuticals, Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on June 10, 2025.
How much is contract 36C25025P1221 worth?
The government has obligated $227,874 on 36C25025P1221.
Was contract 36C25025P1221 competed?
The extent of competition for 36C25025P1221 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award